{
    "2020-08-06": [
        [
            {
                "time": "2020-07-31",
                "original_text": "贝达药业二季业绩下滑严重，年内多次减持 | 中报季 减持股份数",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "二季业绩",
                        "下滑",
                        "减持"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-08-05",
                "original_text": "贝达药业(300558.SZ)：将在区域内启动Balsilimab和Zalifrelimab相关的临床研究",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "临床研究",
                        "Balsilimab",
                        "Zalifrelimab"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "研发"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-08-10",
                "original_text": "贝达药业(300558.SZ)：股东济和创投解除质押1400万股",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "股东",
                        "解除质押",
                        "1400万股"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "资本运作"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-08-15",
                "original_text": "贝达药业(300558)：业绩符合预期 研发与商务合作均有突破",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "业绩",
                        "研发",
                        "商务合作",
                        "突破"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "研发",
                        "合作"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-08-20",
                "original_text": "贝达药业(300558)：业绩整体表现良好 恩沙替尼即将获批",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "业绩",
                        "恩沙替尼",
                        "即将获批"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "新药审批"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-08-25",
                "original_text": "贝达药业(300558)2020年中报点评：上半年埃克替尼业绩亮眼 下半年恩沙替尼有望获批",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "中报",
                        "埃克替尼",
                        "恩沙替尼",
                        "有望获批"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "研发",
                        "新药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-08-30",
                "original_text": "[面包财报] 贝达药业：第二季度归母净利润1332.52万元，同比下降62.61% 盈利能力下降",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "第二季度",
                        "归母净利润",
                        "下降",
                        "盈利能力"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "财务"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-09-05",
                "original_text": "贝达药业：第二季度归母净利润1332.52万元，同比下降62.61% 盈利能力下降",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "第二季度",
                        "归母净利润",
                        "下降",
                        "盈利能力"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "财务"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-09-10",
                "original_text": "贝达药业(300558)：埃克替尼持续稳定增长 研发即将进入收获期",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "埃克替尼",
                        "稳定增长",
                        "研发",
                        "收获期"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "研发"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-09-15",
                "original_text": "贝达药业公布半年报 上半年净利增加64.65%",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "半年报",
                        "净利",
                        "增加"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "财务"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}